CP Maria del Socorro España Lomeli, executive director of the Mexican generics industry association ANAFAM, discusses the challenges with regard to the ‘new rules of the game’ in Mexico’s healthcare sector since 2018, the willingness of the Mexican pharmaceutical industry to be a trusted ally to the public healthcare system, and the importance of ANAFAM members as the suppliers of up to 70 percent of the public system.
If we can align our regulatory processes to those of countries like Canada so that generic drugs can be approved very quickly after the expiry of the innovator patents, then it would help increase generic penetration in Mexico, giving Mexican patients more access to affordable medicines
